{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:03:56Z","timestamp":1783393436165,"version":"3.54.6"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.cbi.2013.06.006","type":"journal-article","created":{"date-parts":[[2013,6,15]],"date-time":"2013-06-15T11:05:37Z","timestamp":1371294337000},"page":"11-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes"],"prefix":"10.1016","volume":"205","author":[{"given":"Soo Hyeon","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eu Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Fen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee Dong","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Hyeon","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Kyung","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2013.06.006_b0005","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/sj.bjp.0707173","article-title":"New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure\u2013activity relationship (3D-QSAR) analysis","volume":"150","author":"Korhonen","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cbi.2013.06.006_b0010","series-title":"Drug\u2013Drug Interactions","first-page":"55","article-title":"Human cytochromes P450 and their role in metabolism-based drug\u2013drug interactions","author":"Clarke","year":"2002"},{"key":"10.1016\/j.cbi.2013.06.006_b0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/157488406775268183","article-title":"Pharmacokinetics and metabolic drug interactions","volume":"1","author":"Leucuta","year":"2006","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2013.06.006_b0020","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2013.06.006_b0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0090-9556(25)06506-7","article-title":"Isoflurane\u2013chlorodifluoroethene interaction in human liver microsomes: role of cytochrome P4502B6 in potentiation of halothane metabolism","volume":"23","author":"Baker","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0030","first-page":"985","article-title":"Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation","volume":"25","author":"Code","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0035","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1081\/DMR-100101942","article-title":"The role of CYP2B6 in human xenobiotic metabolism","volume":"31","author":"Ekins","year":"1999","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.cbi.2013.06.006_b0040","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0090-9556(24)15215-4","article-title":"Monospecific antipeptide antibody to cytochrome P-450 2B6","volume":"27","author":"Stresser","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev.pharmtox.43.100901.140251","article-title":"Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts","volume":"43","author":"Ding","year":"2003","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.cbi.2013.06.006_b0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0028-3908(03)00136-9","article-title":"Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain","volume":"45","author":"Miksys","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cbi.2013.06.006_b0055","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","article-title":"Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression","volume":"307","author":"Lamba","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2013.06.006_b0060","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.cbi.2013.06.006_b0065","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1086\/499369","article-title":"Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance","volume":"42","author":"Nolan","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cbi.2013.06.006_b0070","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/03602539709037591","article-title":"Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors","volume":"29","author":"Rendic","year":"1997","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.cbi.2013.06.006_b0075","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2174\/138920006778520633","article-title":"The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico","volume":"7","author":"Turpeinen","year":"2006","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.cbi.2013.06.006_b0080","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0026-895X(24)12054-8","article-title":"Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity","volume":"28","author":"Faudette","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0085","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0026-895X(24)12046-9","article-title":"CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interaction with other antidepressants","volume":"28","author":"Hesse","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0090","first-page":"5629","article-title":"Differential activation of cyclophosphamide and ifosphamide by cytochrome P-450 2B and 3A in human liver microsomes","volume":"53","author":"Chang","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2013.06.006_b0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/dmd.30.5.525","article-title":"Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism","volume":"30","author":"Rae","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0100","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0090-9556(24)15302-0","article-title":"Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles","volume":"27","author":"Roy","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2013.06.006_b0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/dmd.30.7.853","article-title":"Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes","volume":"30","author":"Hijazi","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0115","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment","volume":"78","author":"Crettol","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2013.06.006_b0120","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","article-title":"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2013.06.006_b0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00000542-200101000-00021","article-title":"Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes","volume":"94","author":"Court","year":"2001","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cbi.2013.06.006_b0130","first-page":"1480","article-title":"CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson\u2019s disease, as revealed from experiments with recombinant enzymes","volume":"29","author":"Hidestrand","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0135","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0090-9556(24)15222-1","article-title":"Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro","volume":"27","author":"Kobayashi","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0140","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/dmd.104.002428","article-title":"Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidase, and glucuronyl transferases in human: an in vitro study","volume":"33","author":"Obach","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0145","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/dmd.108.020727","article-title":"Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N, N-dimethylamine) metabolites in human liver microsomes","volume":"36","author":"Bae","year":"2008","journal-title":"Drug Metab. Disopos."},{"key":"10.1016\/j.cbi.2013.06.006_b0150","first-page":"51","article-title":"Predicting drug\u2013drug interactions in drug discovery: where are we now and where are we going","volume":"8","author":"Hutzler","year":"2005","journal-title":"Curr. Opin. Drug. Discov. Dev."},{"key":"10.1016\/j.cbi.2013.06.006_b0155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1517\/17425255.1.1.49","article-title":"In vitro screening of drug metabolism during drug development: can we trust the predictions","volume":"1","author":"Pelkonen","year":"2005","journal-title":"Expert Opin. Drug. Metab. Toxicol."},{"key":"10.1016\/j.cbi.2013.06.006_b0160","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1124\/dmd.107.015883","article-title":"A comparison of 2-phenyl-2-(1-piperidinyl)propane (PPP),1,1\u2032,1\u2033-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6","volume":"35","author":"Walsky","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0165","first-page":"390","article-title":"Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes","volume":"25","author":"Guo","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1124\/jpet.103.056127","article-title":"Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine","volume":"308","author":"Richter","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2013.06.006_b0175","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1124\/dmd.32.6.626","article-title":"Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro","volume":"32","author":"Turpeinen","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0180","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0090-9556(24)15162-8","article-title":"Mechanism-based inactivation of cytochrome P450 2B1 and 2B6 by 2-phenyl-2-(1-piperidinyl)propane","volume":"28","author":"Chun","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0185","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1124\/jpet.104.069112","article-title":"Metabolism of N, N\u2032, N\u2033-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms","volume":"310","author":"Harleton","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2013.06.006_b0190","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.bcp.2004.10.008","article-title":"Inhibition of human CYP2B6 by N, N\u2032, N\u2033-triethylenethiophosphoramide is irreversible and mechanism-based","volume":"69","author":"Richter","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2013.06.006_b0195","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/rcm.2110","article-title":"High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography\/tandem mass spectrometry","volume":"19","author":"Kim","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.cbi.2013.06.006_b0200","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1124\/dmd.30.12.1311","article-title":"Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions","volume":"30","author":"Yuan","year":"2002","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0205","unstructured":"Draft FDA Guidance for Industry, 2006. Available from: <http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/ucm080499.htm>."},{"key":"10.1016\/j.cbi.2013.06.006_b0210","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug\u2013drug interactions","volume":"35","author":"Obach","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0250","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/00498254.2012.706722","article-title":"Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolite M1 and M2 in relation to CYP2B6\u22176 polymorphism","volume":"43","author":"Pan","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1016\/j.cbi.2013.06.006_b0220","series-title":"Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Systems","author":"Segel","year":"1975"},{"key":"10.1016\/j.cbi.2013.06.006_b0225","first-page":"5","article-title":"An information criterion (AIC)","volume":"14","author":"Akaike","year":"1976","journal-title":"Math. Sci."},{"key":"10.1016\/j.cbi.2013.06.006_b0230","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.tiv.2011.09.023","article-title":"Inhibitory effects of limonin on six human cytochrome P450 enzymes and P-glycoprotein in vitro","volume":"25","author":"Han","year":"2011","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.cbi.2013.06.006_b0235","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/dmd.31.5.606","article-title":"Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions","volume":"31","author":"Margolis","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2013.06.006_b0240","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0006-2952(98)00018-5","article-title":"Inhibitory monoclonal antibody to human cytochrome P450 2B6","volume":"55","author":"Yang","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2013.06.006_b0245","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/dmd.109.031393","article-title":"Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation","volume":"38","author":"Ogburn","year":"2010","journal-title":"Drug Metab. Dispos."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279713001452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279713001452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T13:28:14Z","timestamp":1757856494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279713001452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0009279713001452"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2013.06.006","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2013.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}